Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal investigation of thromboembolism etiology (LITE)

Albert W. Tsai, Mary Cushman, Michael Y. Tsai, Susan R. Heckbert, Wayne D. Rosamond, Nena Aleksic, Norbert Yanez, Bruce M. Psaty, Aaron R. Folsom

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

We sought to examine prospectively the association of serum homocysteine and the methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphism with risk of venous thromboembolism (VTE). We studied these relationships in a nested case-control study of 303 VTE cases and 635 matched controls from a population-based cohort of 21,680 adults from six U.S. communities. The highest quintile of serum homocysteine carried a non-statistically significant adjusted odds ratio of 1.55 (95% CI, 0.93-2.58) compared to the lowest quintile in the overall cohort but a significant association among adults aged 45-64 years (OR = 2.05, 95% CI, 1.10-3.83) and an inverse association in those ≥65 years of age. Carriers of the MTHFR C677T polymorphism were not at higher risk for VTE than those with normal genotype (OR = 0.74, 95% CI = 0.56-0.98). Our prospective data showed, at most, a weak relationship between homocysteine and VTE risk, with associations larger among younger participants. MTHFR C677T was not a risk factor for VTE.

Original languageEnglish (US)
Pages (from-to)192-200
Number of pages9
JournalAmerican Journal of Hematology
Volume72
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Thromboembolism
Venous Thromboembolism
Homocysteine
Serum
Case-Control Studies
Odds Ratio
Genotype
Population
Genes

Keywords

  • Deep vein thrombosis
  • Epidemiology
  • Homocysteine
  • MTHFR
  • Pulmonary embolism

ASJC Scopus subject areas

  • Hematology

Cite this

Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism : Longitudinal investigation of thromboembolism etiology (LITE). / Tsai, Albert W.; Cushman, Mary; Tsai, Michael Y.; Heckbert, Susan R.; Rosamond, Wayne D.; Aleksic, Nena; Yanez, Norbert; Psaty, Bruce M.; Folsom, Aaron R.

In: American Journal of Hematology, Vol. 72, No. 3, 01.03.2003, p. 192-200.

Research output: Contribution to journalArticle

Tsai, Albert W. ; Cushman, Mary ; Tsai, Michael Y. ; Heckbert, Susan R. ; Rosamond, Wayne D. ; Aleksic, Nena ; Yanez, Norbert ; Psaty, Bruce M. ; Folsom, Aaron R. / Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism : Longitudinal investigation of thromboembolism etiology (LITE). In: American Journal of Hematology. 2003 ; Vol. 72, No. 3. pp. 192-200.
@article{643ae9286f3d4dc7951dbe3d8263fdad,
title = "Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal investigation of thromboembolism etiology (LITE)",
abstract = "We sought to examine prospectively the association of serum homocysteine and the methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphism with risk of venous thromboembolism (VTE). We studied these relationships in a nested case-control study of 303 VTE cases and 635 matched controls from a population-based cohort of 21,680 adults from six U.S. communities. The highest quintile of serum homocysteine carried a non-statistically significant adjusted odds ratio of 1.55 (95{\%} CI, 0.93-2.58) compared to the lowest quintile in the overall cohort but a significant association among adults aged 45-64 years (OR = 2.05, 95{\%} CI, 1.10-3.83) and an inverse association in those ≥65 years of age. Carriers of the MTHFR C677T polymorphism were not at higher risk for VTE than those with normal genotype (OR = 0.74, 95{\%} CI = 0.56-0.98). Our prospective data showed, at most, a weak relationship between homocysteine and VTE risk, with associations larger among younger participants. MTHFR C677T was not a risk factor for VTE.",
keywords = "Deep vein thrombosis, Epidemiology, Homocysteine, MTHFR, Pulmonary embolism",
author = "Tsai, {Albert W.} and Mary Cushman and Tsai, {Michael Y.} and Heckbert, {Susan R.} and Rosamond, {Wayne D.} and Nena Aleksic and Norbert Yanez and Psaty, {Bruce M.} and Folsom, {Aaron R.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1002/ajh.10287",
language = "English (US)",
volume = "72",
pages = "192--200",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism

T2 - Longitudinal investigation of thromboembolism etiology (LITE)

AU - Tsai, Albert W.

AU - Cushman, Mary

AU - Tsai, Michael Y.

AU - Heckbert, Susan R.

AU - Rosamond, Wayne D.

AU - Aleksic, Nena

AU - Yanez, Norbert

AU - Psaty, Bruce M.

AU - Folsom, Aaron R.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - We sought to examine prospectively the association of serum homocysteine and the methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphism with risk of venous thromboembolism (VTE). We studied these relationships in a nested case-control study of 303 VTE cases and 635 matched controls from a population-based cohort of 21,680 adults from six U.S. communities. The highest quintile of serum homocysteine carried a non-statistically significant adjusted odds ratio of 1.55 (95% CI, 0.93-2.58) compared to the lowest quintile in the overall cohort but a significant association among adults aged 45-64 years (OR = 2.05, 95% CI, 1.10-3.83) and an inverse association in those ≥65 years of age. Carriers of the MTHFR C677T polymorphism were not at higher risk for VTE than those with normal genotype (OR = 0.74, 95% CI = 0.56-0.98). Our prospective data showed, at most, a weak relationship between homocysteine and VTE risk, with associations larger among younger participants. MTHFR C677T was not a risk factor for VTE.

AB - We sought to examine prospectively the association of serum homocysteine and the methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphism with risk of venous thromboembolism (VTE). We studied these relationships in a nested case-control study of 303 VTE cases and 635 matched controls from a population-based cohort of 21,680 adults from six U.S. communities. The highest quintile of serum homocysteine carried a non-statistically significant adjusted odds ratio of 1.55 (95% CI, 0.93-2.58) compared to the lowest quintile in the overall cohort but a significant association among adults aged 45-64 years (OR = 2.05, 95% CI, 1.10-3.83) and an inverse association in those ≥65 years of age. Carriers of the MTHFR C677T polymorphism were not at higher risk for VTE than those with normal genotype (OR = 0.74, 95% CI = 0.56-0.98). Our prospective data showed, at most, a weak relationship between homocysteine and VTE risk, with associations larger among younger participants. MTHFR C677T was not a risk factor for VTE.

KW - Deep vein thrombosis

KW - Epidemiology

KW - Homocysteine

KW - MTHFR

KW - Pulmonary embolism

UR - http://www.scopus.com/inward/record.url?scp=0037373178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037373178&partnerID=8YFLogxK

U2 - 10.1002/ajh.10287

DO - 10.1002/ajh.10287

M3 - Article

C2 - 12605391

AN - SCOPUS:0037373178

VL - 72

SP - 192

EP - 200

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -